Chemotherapy-Induced Febrile Neutropenia
"Chemotherapy-Induced Febrile Neutropenia" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
FEVER accompanied by a significant reduction in NEUTROPHIL count associated with CHEMOTHERAPY.
| Descriptor ID |
D064146
|
| MeSH Number(s) |
C15.378.553.546.184.564.750.500
|
| Concept/Terms |
Chemotherapy-Induced Febrile Neutropenia- Chemotherapy-Induced Febrile Neutropenia
- Chemotherapy Induced Febrile Neutropenia
- Chemotherapy-Induced Febrile Neutropenias
- Febrile Neutropenia, Chemotherapy-Induced
- Febrile Neutropenias, Chemotherapy-Induced
- Neutropenia, Chemotherapy-Induced Febrile
- Neutropenias, Chemotherapy-Induced Febrile
- Drug-Induced Febrile Neutropenia
- Drug Induced Febrile Neutropenia
- Drug-Induced Febrile Neutropenias
- Febrile Neutropenia, Drug-Induced
- Febrile Neutropenias, Drug-Induced
- Neutropenia, Drug-Induced Febrile
- Neutropenias, Drug-Induced Febrile
|
Below are MeSH descriptors whose meaning is more general than "Chemotherapy-Induced Febrile Neutropenia".
Below are MeSH descriptors whose meaning is more specific than "Chemotherapy-Induced Febrile Neutropenia".
This graph shows the total number of publications written about "Chemotherapy-Induced Febrile Neutropenia" by people in this website by year, and whether "Chemotherapy-Induced Febrile Neutropenia" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2017 | 3 | 1 | 4 |
| 2018 | 2 | 0 | 2 |
| 2019 | 0 | 1 | 1 |
| 2020 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Chemotherapy-Induced Febrile Neutropenia" by people in Profiles.
-
Granulocyte colony-stimulating factors (G-CSF) and Covid-19: a double-edged sword? Infez Med. 2020 Sep 01; 28(3):459-460.
-
Personalized cancer supportive care in COVID-19 era. Ann Oncol. 2020 07; 31(7):835-837.
-
Phase II Study of Tivantinib and Cetuximab in Patients With KRAS Wild-type Metastatic Colorectal Cancer With Acquired Resistance to EGFR Inhibitors and Emergence of MET Overexpression: Lesson Learned for Future Trials With EGFR/MET Dual Inhibition. Clin Colorectal Cancer. 2019 06; 18(2):125-132.e2.
-
Integrative omics to detect bacteremia in patients with febrile neutropenia. PLoS One. 2018; 13(5):e0197049.
-
Galactomannan Antigen Test for Early Diagnosis of Invasive Aspergillus Infection in Pediatric Febrile Neutropenia. Indian Pediatr. 2018 03 15; 55(3):257-258.
-
Myeloid Growth Factors, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 12; 15(12):1520-1541.
-
A Patient Risk Model of Chemotherapy-Induced Febrile Neutropenia: Lessons Learned From the ANC Study Group. J Natl Compr Canc Netw. 2017 12; 15(12):1543-1550.
-
Etiology of community-onset monomicrobial bacteremic pneumonia and its clinical presentation and outcome: Klebsiella and Pseudomonas matters. J Infect Chemother. 2018 Jan; 24(1):53-58.
-
History and outcome of febrile neutropenia related to non-chemotherapy drugs: A retrospective study of the Strasbourg's agranulocytosis cohort. Eur J Intern Med. 2017 Dec; 46:e13-e14.